RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q4 2019
Top Holdings34 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
Synthorx Inc | 9.7M | $679.7M | 20.6% | — | — | 5 qtrssince 2018-Q4 | Unchanged 0 |
ASCENDIS PHARMA A/S | 4.2M | $582.3M | 17.7% | $60.85 | +123.45% | 5 qtrssince 2018-Q4 | Increased 63 |
RA PHARMACEUTICALS INC | 4.9M | $228M | 6.9% | — | — | 5 qtrssince 2018-Q4 | Unchanged 0 |
ARVINAS INC | 3.7M | $150.9M | 4.6% | $29.09 | +45.34% | 5 qtrssince 2018-Q4 | Increased 91 |
| 3.2M | $126.5M | 3.8% | — | — | 1 qtr | New 84 | |
RHYTHM PHARMACEUTICALS INC | 5.4M | $124.5M | 3.8% | $23.88 | -3.80% | 5 qtrssince 2018-Q4 | Increased 80 |
EIDOS THERAPEUTICS INC | 2.2M | $124.1M | 3.8% | — | — | 5 qtrssince 2018-Q4 | Unchanged 0 |
ZOGENIX INC | 2.3M | $117.9M | 3.6% | — | — | 5 qtrssince 2018-Q4 | Unchanged 0 |
PHATHOM PHARMACEUTICALS INC | 3.6M | $113.6M | 3.4% | $32.50 | 0.00% | 1 qtr | New 84 |
TG Therapeutics, Inc. | 9.9M | $109.7M | 3.3% | $6.07 | +78.87% | 5 qtrssince 2018-Q4 | Increased 75 |
SATSUMA PHARMACEUTICALS INC | 4.7M | $92.1M | 2.8% | — | — | 2 qtrssince 2019-Q3 | Unchanged 0 |
ORCHARD THERAPEUTICS PLC | 6.4M | $87.9M | 2.7% | — | — | — | — |
89BIO INC | 3.2M | $83.1M | 2.5% | — | — | 1 qtr | New 78 |
FORTY SEVEN INC | 1.9M | $76.1M | 2.3% | — | — | 1 qtr | New 78 |
WAVE LIFE SCIENCES LTD | 7.8M | $62.3M | 1.9% | $42.17 | -81.05% | 5 qtrssince 2018-Q4 | Unchanged 0 |
| 4.3M | $60.4M | 1.8% | — | — | — | Increased 51 | |
Boundless Bio, Inc. | 902,383 | $54M | 1.6% | — | — | 1 qtr | New 68 |
PREVAIL THERAPEUTICS INC | 3.4M | $53.2M | 1.6% | — | — | 3 qtrssince 2019-Q2 | Unchanged 0 |
CRINETICS PHARMACEUTICALS IN | 1.9M | $47M | 1.4% | $30.51 | -22.29% | 5 qtrssince 2018-Q4 | Unchanged 0 |
ARDELYX INC | 5.4M | $40.2M | 1.2% | $7.43 | 0.00% | 1 qtr | New 67 |
RA CAPITAL MANAGEMENT, L.P. manages $3.3B across 34 positions as of Q4 2019. Top holdings: THOR (20.6%), ASND (17.7%), RARX (6.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 9 new positions, 7 exits, 7 increased. Top move: ARVN (INCREASED, conviction 91). Portfolio: $3.3B across 34 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer